Acquisition Completed
Quince Therapeutics acquisition of Orphai Therapeutics
Announced 18 May 2026
Advisers
Quince Therapeutics
Acquirer
- Financial adviser
- Legal adviser
- Fairness opinion
- Target
- Orphai Therapeutics
- Acquirer
- Quince Therapeutics
- Target based in
- United States
- Buyer based in
- United States
- Completed
- 18 May 2026
- Sector
- Biotech
- Tags
- Biotech, Pharma, Rare Disease
In the league tables
- M&A financial advisers, 2026 to date LifeSci Capital #145
- M&A financial advisers, completed, 2026 to date LifeSci Capital #89
- M&A legal advisers, 2026 to date Gibson Dunn #16 · Cooley #28 · Dorsey & Whitney #80
- M&A legal advisers, completed, 2026 to date Gibson Dunn #11 · Cooley #22 · Dorsey & Whitney #99
- Fairness opinion providers, 2026 to date Oppenheimer & Co. #25
Similar deals
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Chiesi Group acquisition of KalVista Pharmaceuticals Apr 2026 · US$1.9bn · Pharma
- Neurocrine Biosciences acquisition of Soleno Therapeutics Apr 2026 · US$2.9bn · Biotech
- BioMarin acquisition of Amicus Therapeutics Dec 2025 · US$4.8bn · Biotech
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
Sources
- 18 May 2026 Press release (EX-99.1, exhibit), Quince Announces Acquisition of Orphai and up to $187 Million Private sec.gov
- 18 May 2026 Orphai Therapeutics Sale to Quince Therapeutics cooley.com
- 20 May 2026 Gibson Dunn Advised LifeSci Capital as Financial Advisor in Quince Therapeutics’ Acquisition of Orphai Therapeutics and Concurrent Private Placement Financing gibsondunn.com
